The peptides everyone is talking about
Updated November 20, 2026
- 1
Retatrutide cut sleep apnea events by up to 34 an hour in two phase 3 trials
In NEJM (online Oct 21, 2026) and in Lilly's ObesityWeek data on Nov 15, 2026, the 9 mg and 12 mg doses cut breathing events by 24.7 to 34.3 per hour over 80 weeks vs about 10 on placebo, in 691 adults with sleep apnea and a BMI of 27 or higher. Retatrutide is investigational and not approved, and the 4 mg dose did not reach statistical significance.
What TRIUMPH-OSA found →Source: Healio: TRIUMPH-OSA, retatrutide reduces sleep apnea severity in OSA plus obesity (Nov 11, 2026)
- 2
Lower doses of CagriSema still delivered about 21% weight loss
At ObesityWeek on Nov 14, 2026, REDEFINE 9 (309 adults, 68 weeks, Lancet Diabetes & Endocrinology) found 20.7% and 21.0% average weight loss on the 1.7 mg and 1.0 mg doses vs 2.0% on placebo (efficacy estimand; 19.4% and 18.6% vs 4.6% counting everyone). CagriSema is not FDA-approved yet, with a decision on the 2.4 mg dose expected in Q4 2026.
What REDEFINE 9 found →Source: Novo Nordisk: CagriSema ~21% average weight loss with lower doses in REDEFINE 9 (Nov 14, 2026)
- 3
Novo's free NovoCare program adds home delivery and support for Wegovy
On Nov 17, 2026 Novo relaunched NovoCare as a free membership with refill help, coaching and home delivery for the Wegovy pill and injection: live now for self-pay, and coming in the next weeks for commercial, government and Medicare Bridge coverage. Wegovy (semaglutide, graded A) is FDA-approved but still needs a prescription, some plans need prior authorization, and the release announces no new prices.
GLP-1 price tracker →Source: Novo Nordisk: Novo launches the new Novocare free support program for Wegovy (Nov 17, 2026)
- 4
A daily GLP-1 pill improved sleep apnea in two phase 3 trials
In JAMA on Nov 9, 2026, Lilly's Foundayo cut breathing events by 17.8 vs 4.5 per hour on placebo without CPAP, and 17.3 vs 5.3 with CPAP, over 52 weeks. It is approved for weight management only, not sleep apnea, and stomach side effects were common (68.0% vs 37.4% on placebo in trial 1).
What ATTAIN-OSA found →Source: JAMA: Orforglipron for Obstructive Sleep Apnea (ATTAIN-OSA), Nov 9, 2026
- 5
HHS's interim pharmacy lane for six peptides moves past public comment
Comments on HHS's draft enforcement discretion policy for compounding BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon closed Nov 13, 2026 (Federal Register, Oct 30). It approves no peptide and lasts only until FDA rules on each one; five of the six are graded D and Semax is graded C.
What the HHS policy says →Source: Arnold & Porter: HHS announces draft enforcement discretion policy for peptide compounding (Nov 2, 2026)
How we pick: each week we look at new trials, FDA and advisory committee actions, price changes and what people are searching for, then explain the real story behind the buzz. Being on this list is not a recommendation. Check each one's Peptiblox Score and thelegal status tracker.